{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:28Z","timestamp":1788798448631,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>cGMP-dependent protein kinase 1 (PRKG1) has shown to be associated with some tumorigenesis, while the role of PRKG1 in bladder cancer is unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To investigate the biological and clinical significance of PRKG1 in bladder cancer, we detected the expression of PRKG1 and explored the function of PRKG1 in bladder cancer cells. The PRKG1 transcripts data was downloaded from The Cancer Genome Atlas (TCGA) database, and immunohistochemistry staining was conducted on formalin-fixed paraffin-embedded (FFPE) sample tissues. Relationship between clinical characteristics of patients and expression of PRKG1 was analyzed in FFPE samples, TCGA database, and GSE19423 dataset. PRKG1 was over-expressed, and cell proliferation, migration, invasion, apoptosis, and spheroidizing ability were then detected. Chemosensitivity to cisplatin was detected with cell viability, and half-maximal drug inhibitory concentration (IC50) was calculated. In addition, the relation between PRKG1 expression and the infiltration level of tumor immune cells in tumor microenvironment were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results showed expression of PRKG1 was lower in bladder cancer, compared with normal tissues both at protein and transcript levels. Lower PRKG1 expression was related to higher tumor grade, T stage, and muscle invasion, also predicted worse overall survival and recurrence free survival in patients treated with Bacillus Calmette\u2013Guerin (BCG) intravesical immunotherapy. Analysis of tumor immune cells infiltration showed lower PRKG1 was associated with non-inflamed tumor microenvironment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study firstly identified the anti-tumor role and tumor immune regulatory role of PRKG1, also found loss of PRKG1 could be used as a prognosis factor. The present study provided a potential biomarker and therapy target to bladder cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1442555","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:27:09Z","timestamp":1722313629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The clinical significance and anti-tumor role of PRKG1 in bladder cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Lu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40779-022-00406-y","article-title":"Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline, (2021 edition)","volume":"9","author":"Jin","year":"2022","journal-title":"Mil Med Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.11.005","article-title":"5-Year outcome of a randomized prospective study comparing bacillus Calmette-Gu\u00e9rin with epirubicin and interferon-\u03b12b in patients with T1 bladder cancer","volume":"191","author":"Hemdan","year":"2014","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100938","DOI":"10.1016\/j.drup.2023.100938","article-title":"Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms","volume":"68","author":"Li","year":"2023","journal-title":"Drug Resist Update"},{"key":"B7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/cancers16010125","article-title":"SIRT1 promotes cisplatin resistance in bladder cancer via beclin1 deacetylation-mediated autophagy","volume":"16","author":"Sun","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.602803","article-title":"Targeting the malaria parasite cGMP-dependent protein kinase to develop new drugs","volume":"11","author":"Baker","year":"2020","journal-title":"Front Microbiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-68964-5_17","article-title":"cGMP-dependent protein kinase modulators","volume":"191","author":"Butt","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ph6020269","article-title":"cGMP-dependent protein kinase inhibitors in health and disease","volume":"6","author":"Wolfertstetter","year":"2013","journal-title":"Pharm (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2005.08.035","article-title":"An anti-tumor role for cGMP-dependent protein kinase","volume":"240","author":"Hou","year":"2006","journal-title":"Cancer Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41419-023-05580-y","article-title":"Increased endogenous PKG I activity attenuates EGF-induced proliferation and migration of epithelial ovarian cancer via the MAPK\/ERK pathway","volume":"14","author":"Lan","year":"2023","journal-title":"Cell Death Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"PO.17.00073","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"110065","DOI":"10.1016\/j.cellsig.2021.110065","article-title":"Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation","volume":"86","author":"Yang","year":"2021","journal-title":"Cell Signal"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.54442","article-title":"USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway","volume":"17","author":"He","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17678","DOI":"10.1038\/s41598-021-97212-8","article-title":"Epigallocatechin gallate inhibits release of extracellular vesicles from platelets without inhibiting phosphatidylserine exposure","volume":"11","author":"Millington-Burgess","year":"2021","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02770903.2024.2303763","article-title":"Association between prkg1 gene and gene-environment interactions with pediatric asthma","volume":"61","author":"Liu","year":"2024","journal-title":"J Asthma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15844","article-title":"The NO\/cGMP\/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders","volume":"20","author":"Degjoni","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-050410-100030","article-title":"Structure and regulation of soluble guanylate cyclase","volume":"81","author":"Derbyshire","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2017.1344400","article-title":"The latest advances in the discovery of nitric oxide hybrid drug compounds","volume":"12","author":"Serafim","year":"2017","journal-title":"Expert Opin Drug Discovery"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15856","article-title":"Nitric oxide-cGMP signaling in hypertension: current and future options for pharmacotherapy","volume":"76","author":"Ataei Ataabadi","year":"2020","journal-title":"Hypertension"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s6392","article-title":"The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension","volume":"6","author":"Falk","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.594","article-title":"Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study","volume":"174","author":"Li","year":"2014","journal-title":"JAMA Intern Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.02.028","article-title":"Sildenafil potentiates a cGMP-dependent pathway to promote melanoma growth","volume":"14","author":"Dhayade","year":"2016","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-4644","article-title":"Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells","volume":"94","author":"Zhu","year":"2005","journal-title":"J Cell Biochem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.04.148","article-title":"cGMP-dependent protein kinase I promotes cell apoptosis through hyperactivation of death-associated protein kinase 2","volume":"422","author":"Isshiki","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/biomedicines11010069","article-title":"Molecular subtyping in muscle-invasive bladder cancer on predicting survival and response of treatment","volume":"11","author":"Bejrananda","year":"2022","journal-title":"Biomedicines"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01354-4","article-title":"Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut-lung axis","volume":"23","author":"Jeyanathan","year":"2022","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3390\/cells13080699","article-title":"Breaking barriers: modulation of tumor microenvironment to enhance bacillus calmette-gu\u00e9rin immunotherapy of bladder cancer","volume":"13","author":"Ibrahim","year":"2024","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-\u03b3 signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus calmette-gu\u00e9rin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005518","article-title":"Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections","volume":"11","author":"Van Puffelen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190456","article-title":"Targeting the interleukin-17 immune axis for cancer immunotherapy","volume":"217","author":"Vitiello","year":"2020","journal-title":"J Exp Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1442555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:27:13Z","timestamp":1722313633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1442555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2024.1442555"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1442555","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"article-number":"1442555"}}